DDX5 and neoplasm: Hyperphosphorylated DDX5 (p-DDX5) is enriched in FP-RMS, and pharmacological targeting of this form with RX-5902—a small molecule that blocks DDX5–β-catenin interaction—has shown promising anti-tumor activity.